Cosopt/Cosopt-S Dosage/Direction for Use

Cosopt: The dose is one drop of DORZOLAMIDE HCl + TIMOLOL MALEATE (COSOPT) in the affected eye(s) two times daily.
When substituting DORZOLAMIDE HCl + TIMOLOL MALEATE (COSOPT) for another ophthalmic antiglaucoma agent(s), discontinue the other agent(s) after proper dosing on one day, and start DORZOLAMIDE HCl + TIMOLOL MALEATE (COSOPT) on the next day.
If another topical ophthalmic agent is being used, DORZOLAMIDE HCl + TIMOLOL MALEATE (COSOPT) and the other agent should be administered at least ten minutes apart.
Safety and efficacy in pediatric patients below the age of 2 years have not been established. (For information regarding use in pediatric patients ≥2 years of age see Use in Children under Precautions.)
When using nasolacrimal occlusion or closing the eyelids for 2 minutes, the systemic absorption is reduced. This may result in an increase in local activity.
Mode of Administration: The dose is one drop of DORZOLAMIDE HCl + TIMOLOL MALEATE (COSOPT) in the affected eye(s) two times daily.
Cosopt-S: Dosage: The dose is one drop of Dorzolamide HCl/Timolol Maleate (Cosopt-S) in the (conjunctival sac of the) affected eye(s) two times daily.
If another topical ophthalmic agent is being used, Dorzolamide HCl/Timolol Maleate (Cosopt-S) and the other agent should be administered at least ten minutes apart.
This medicinal product is a sterile solution that does not contain a preservative. The solution from one individual single dose container is to be used immediately after opening for administration to the affected eye(s). Since sterility cannot be maintained after the individual single dose container is opened, any remaining contents must be discarded immediately after administration.
Patients should be instructed to wash their hands before use and avoid allowing the container to come into contact with the eye or surrounding structures as this could cause injury to the eye (see Instructions for Use under Cautions for Usage).
Patients should also be instructed that ocular solutions, if handled improperly, can become contaminated by common bacteria known to cause ocular infections. Serious damage to the eye and subsequent loss of vision may result from using contaminated solutions.
When using nasolacrimal occlusion or closing the eyelids for 2 minutes, the systemic absorption is reduced. This may result in a decrease in systemic side effects and an increase in local activity.
Administration: Since different shapes of the single-dose containers are available, patients should be informed of the correct handling of the single-dose container. Please see Instructions for use for shape-specific diagrams and instructions for use.
Paediatric population: Efficacy in paediatric patients has not been established.
Safety in paediatric patients below the age of 2 years has not been established (For information regarding safety in paediatric patients ≥2 and <6 years of age).